Recognition surfaces of MHC class I

Immunological Reviews

Volumn 163, Issue , 1998, Pages 121-128

  Jones, E Yvonne ^a,b   Tormo, José ^a,b,c   Reid, Scott W ^a,d   Stuart, David I ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DEPT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^d Axys Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ANTIBODY AFFINITY; CRYSTAL STRUCTURE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN TERTIARY STRUCTURE; REVIEW;

ANIMALS; ANTIGENS, CD8; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL;

EID: 0031818638     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01191.x     Document Type: Review

References (45)

1. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cyto-toxic T-lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-968.
2. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-624.
3. Garcia KC, et al. CD8 enhances formation of stable T-cell receptor/MHC class I complexes. Nature 1996;384:577-581.
4. Matsui K, et al. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991;254:1788-1791.
5. Weber S, Traunecker A, Oliver F, Gerhad W, Karjalainen K. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 1992;356:793-796.
6. Garcia KC, et al. An αβ T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996;274:209-219.
7. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134-141.
8. Garcia KC, et al. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166-1172.
9. Gao GF, et al. Crystal structure of the complex between human CD8αα and HLA-A2. Nature 1997;387:630-634.
10. Reid SW et al. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J Exp Med 1996;184:2279-2286.
11. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-459.
12. Couillin I, Culman-Penciolelli B, Gomard E, Levy J-P, Guillet J-G, Saragosti S. Impaired CTL recognition due to genetic variations in the main immunogenic region of the HIV-1 nef protein. J Exp Med 1994;180:1129-1134.
13. Meier U-C, et al. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 1995;270:1360-1362.
14. Klenerman P, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994;369:403-407.
15. Bertoletti A, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-410.
16. Gilbert SC, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998;279:1173-1177.
17. Nowak MA, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
18. McAdam S, et al. Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-2736.
19. Lyons DS, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996;5:53-61.
20. Jameson SC, Bevan MJ. T cell receptor antagonists and partial agonists. Immunity 1995;2:1-11.
21. McKeithan T. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci USA 1995;92:5042-5046.
22. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. Kinetic discrimination in T-cell activation. Proc Natl Acad Sci USA 1996;93:1401-1405.
23. Zamoyska R. The CD8 coreceptor revisited: one chain good, two chains better. Immunity 1994;1:243-246.
24. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989;44:265-311.
25. Leahy DJ, Axel R, Hendrickson WA. Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6Å resolution. Cell 1992;68:1145-1162.
26. Norment AM, Salter RD, Parham P, Engelhard VH, Littman DR. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature 1988;336:79-81.
27. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-512.
28. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995;13:587-622.
29. Salter RD, et al. Polymorphism in the a3 domain of HLA-A molecules affects binding to CD8. Nature 1989;338:345-347.
30. Salter RD, et al. A binding site for the T-cell co receptor CD8 on the α3 domain of HLA-A2. Nature 1990;345:41-46.
31. Sun J, Leahy DJ, Kavathas PB. Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the alpha 2 and alpha 3 domains of MHC class I. J Exp Med 1995;182:1275-1280.
32. Giblin PA, Leahy DJ, Mennone J, Kavathas PB. The role of charge and multiple faces of the CD8 alpha/alpha homodimer in binding to major histocompatibility complex class I molecules: support for a bivalent model. Proc Natl Acad Sci USA 1994;91:1716-1720.
33. Madden D, Garboczi D, Wiley D. The antigenic identity of peptide/mhc complexes: a comparison of the conformations of five peptides presented by HLA-A2. Cell 1993;75:693-708.
34. Kirszbaum L, Sharpe JA, Goss N, Lahnstein J, Walker ID. The alpha-chain of murine CD8 lacks an invariant Ig-like disulfide bond but contains a unique intrachain loop instead. J Immunol 1989;142:3931-3936.
35. Williams AF, Barclay AN. The immunoglobulin superfamily - domains for cell surface recognition. Annu Rev Immunol 1988;6:381-405.
36. Wilson IA, Stanfield RL. Antibody-antigen interaction: new structures and new conformational changes. Curr Opin Struct Biol 1994;4:857-867.
37. Lawrence MC, Colman PM. Shape complementarity at protein-protein interfaces. J Mol Biol 1993;324:946-950.
38. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 1996;17:177-187.
39. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267:383-386.
40. Esnouf RM. BOBSCRIPT: an extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J Mol Graph 1997;15:133-138.
41. Merritt EA, Murphy MEP. Raster 3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr D 1994;50:869-873.
42. Stuart DI, Levine M, Muirhead M, Stammers D. The crystal structure of cat pyruvate kinase at a resolution of 2.6 Å. J Mol Biol 1979;134:109-142.
43. Tormo J, Blaas D, Parry NR, Rowlands D, Stuart D, Fita I. Crystal-structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid pro-tein VP2. EMBO J 1994;13:2247-2256.
44. Jones EY, Davis SJ, Williams AF, Harlos K, Stuart DI. Crystal structure at 2.8 Å resolution of a soluble form of the cell adhesion molecule CD2. Nature 1992;360:232-239.
45. Bodian DL, Jones EY, Harlos K, Stuart DI, Davis SJ. Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 Å resolution. Structure 1994;2:755-766.